|
|
|
| Clinical effect of Aripiprazole and Risperidone in the treatment of schizophrenia and comparison of their effect on glucose and lipid metabolism |
| QU Jin-mei |
| Department of Pharmacy, Jiuquan People′s Hospital, Gansu Province, Jiuquan 735000, China |
|
|
|
|
Abstract Objective To explore the clinical effect of Aripiprazole and Risperidone in the treatment of schizophrenia and comparisons of their effect on glucose and lipid metabolism. Methods Seventy patients with schizophrenia in Jiuquan People′s Hospital from June 2018 to August 2019 were selected as the research subjects. They were divided into a control group and an observation group by the random number table method, with 35 cases in each group. The patients in the control group were treated with Risperidone, and the patients in the observation group were treated with Aripiprazole. The blood glucose, blood lipid levels and clinical efficacy of the two groups of patients were compared.Results Before treatment, there were no statistically significant differences in the levels of fasting blood glucose (FBG)or 2-hour postprandial glucose (2 h PG) between the two groups (P>0.05). After treatment, the FBG and 2 h PG levels of the observation group were lower than those of the control group, the differences were statistically significant (P<0.05). The levels of FBG and 2 h PG in the two groups after treatment were higher than those before treatment, the differences were statistically significant (P<0.05). Before treatment, there were no significant differences in the levels of cholesterol (TC), triacylglycerol (TG), or low-density lipoprotein cholesterol (LDL-C) between the two groups. After treatment, the levels of TC, TG and LDL-C in the observation group were lower than those in the control group, the differences were statistically significant (P<0.05). The HDL-C level of observation group was higher than that in the control group after treatment, the difference was statistically significant (P<0.05). The total effective rate of observation group was higher than that in the control group, the difference was statistically significant (P<0.05). Conclusion Compared with Risperidone, Aripiprazole has a significant effect on treating patients with schizophrenia, and can remarkably improve the blood glucose and blood lipid levels, which is worthy of promotion.
|
|
|
|
|
|
| [1] |
黄海燕，潘江艳，韦云龙，等.住院老年精神分裂症患者服用奥氮平和利培酮后对糖脂代谢及认知能力的影响[J].国际精神病学杂志，2016，43（5）：797-799.
|
| [2] |
陈景华.阿立哌唑与利培酮对女性精神分裂症患者腹部脂肪量及分布的影响[J].现代中西医结合杂志，2016，25（3）：295-297.
|
| [3] |
王树锋，张云淑，栗克清.精神分裂症患者短期治疗过程中同型半胱氨酸水平与糖脂代谢变化的关系[J].中国神经精神疾病杂志，2018，44（6）：360-364.
|
| [4] |
王锋，柳和春，刘小松，等.不同来源ω-3 多不饱和脂肪酸对2 型糖尿病合并血脂异常人群糖脂代谢的影响[J].中华预防医学杂志，2019，53（6）：570-575.
|
| [5] |
美国精神医学学会，张道龙.精神疾病诊断与统计手册[J].北京大学医学出版社，2014，11（9）：109.
|
| [6] |
杜雪萍.抗精神病药物对精神分裂症患者血脂水平的影响[J].心血管病防治知识，2020，10（25）：30-31.
|
| [7] |
刘燕菁，覃颖.阿立哌唑与利培酮对精神分裂症患者糖脂代谢及PRL 水平的影响[J].现代医学与健康研究电子杂志，2020，4（17）：52-54.
|
| [8] |
孙美玲.阿立哌唑联合利培酮治疗精神分裂症患者的效果研究[J].中国医药指南，2020，18（32）：97-98.
|
| [9] |
汪莉，隋云川，徐乐平，等.二甲双胍对奥氮平致体重增加精神分裂症患者肝脏脂肪含量的影响[J].中华精神科杂志，2016，49（1）：36-41.
|
| [10] |
安邦，赵珊珊，高惠荣，等.精神分裂症患者并发脂肪肝的相关因素分析[J].中国医药导报，2020，17（32）：108-111.
|
| [11] |
梅玫.优质护理在精神分裂症患者中的应用价值研究[J].中国医药科学，2020，10（10）：108-111.
|
| [12] |
Lindholm E，Cavelier L，Howell WM，et al.Mitochondrial sequence variants in patients with schizophrenia[J].Eur J Hum Genet，2019，5（6）：406-412.
|
| [13] |
李博文，何金娜.精神分裂症患者认知功能损害的影响因素分析[J].中国医药科学，2019，9（9）：247-250.
|
| [14] |
张婷，饶庆敏，许莹，等.精神分裂症患者CYP2D6基因多态性与利培酮代谢的相关性研究[J].中华检验医学杂志，2019，42（4）：306-311.
|
| [15] |
房玲玲，李小燕，胡玲玲，等.代餐与低能量均衡饮食对减重效果及糖脂代谢的影响比较[J].中华内分泌代谢杂志，2019，35（1）：47-52.
|
| [16] |
García-Ruiz AJ，Pérez-Costillas L，Montesinos AC，et al.Costeffectiveness analysis of antipsychotics in reducing schizophrenia relapses[J].Health Econ Rev，2019，2（1）：8.
|
| [17] |
易伟华.利培酮与阿立哌唑治疗精神分裂症的临床效果比较[J].临床合理用药杂志，2020，13（29）：45-47.
|
| [18] |
孙春明，吕成荣，那爱国，等.利培酮联合阿立派唑治疗监狱老年精神分裂症的效果及对QTc 间期的影响[J].中外医学研究，2020，18（21）：27-29.
|
| [19] |
雷秀萍，郭燕，赵玲丹.牛黄宁宫片联合阿立哌唑治疗精神分裂症的效果[J].中国医药导报，2019，16（31）：123-126.
|
|
|
|
